Rebecca L. Olin

Rebecca L. Olin

Hematology | Hematology Oncology
400 Parnassus Ave.
Fourth Floor
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood
Published: May 04, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Journal: American journal of hematology
Published: April 02, 2026

Eligibility versus appropriateness in allogeneic HCT.

Eligibility versus appropriateness in allogeneic HCT.

Journal: Blood advances
Published: March 02, 2026

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Journal: Blood advances
Published: November 19, 2025

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Journal: Blood advances
Published: November 19, 2025

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study.

Journal: Blood advances
Published: September 08, 2025

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.

Journal: Blood advances
Published: September 08, 2025

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

Journal: Haematologica
Published: July 24, 2025

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 12, 2025
Showing 1-12 of 80

Last Updated: 09/26/2026